Clinical trials: Connective Tissue Disease
Acral Lentiginous Malignant Melanoma, Lentigo Maligna Malignant Melanoma
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
This phase II trial is studying how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with stage IV melanoma.
- Conditions
- Acral Lentiginous Malignant Melanoma, Lentigo Maligna Malignant Melanoma, Nodular Malignant Melanoma, Recurrent Melanoma
- Trial name
- NCT01120275
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis
- Where
- 178 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Postoperative Pain
Liposomal Bupivacaine in Implant Based Breast Reconstruction
Objectives: 1. To evaluate the effect of liposomal bupivacaine on postoperative pain levels. 2. To evaluate the effect of liposomal bupivacaine on postoperative opioid consumption and opioid related adverse events. 3.
- Trial name
- NCT02659501
- Testing
- Liposomal bupivacaine, Bupivacaine with epinephrine, Morphine sulfate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Loma Linda University
Rheumatoid Arthritis
First in Human Study of a Monoclonal Antibody (SOL-116) Targeting BSSL (Bile Salt-Stimulated Lipase), Single and Multiple Dose Parts
This is a randomized, double-blind, placebo-controlled, first-in-human phase I study. It consists of a single ascending dose part in healthy subjects (Part 1) and in patients with rheumatoid arthritis (Part 2) as well as a…
- Trial name
- NCT05576012
- Testing
- SOL-116
- Where
- 2 sites in Netherlands
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Lipum AB
External Genital Warts
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
The LFX453X2202 study tested the investigational drug LFX453 against placebo for safety, tolerability, and efficacy in treating genital warts in circumcised men, in parallel with an additional open label arm using imiquimod 5%.
- Trial name
- NCT02482428
- Testing
- Investigational Treatment, Aldara
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Trial of RAD001 in Triple Negative Metastatic Breast Cancer
The hypothesis of this clinical research study is to discover if the study drug RAD001 can shrink or slow the growth of Estrogen Receptor/Progesterone Receptor (ER/PR) negative or Human Epidermal growth factor Receptor 2 (Her2…
- Trial name
- NCT00827567
- Testing
- RAD 001
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Milton S. Hershey Medical Center
Fluid Loss, Symptom Complex, Triple
Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation
Administration of intravascular (IV) fluid is the most common emergency department (ED) procedure. IV fluids are integral to increasing effective blood volume and ensuring organ perfusion in patients with volume depletion and…
- Conditions
- Fluid Loss, Symptom Complex, Triple, Emergencies
- Trial name
- NCT03133767
- Testing
- Lactated Ringer Solution, Normal Saline 0.9% Infusion Solution Bag
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- Nicholas M Mohr
Rheumatoid Arthritis, Psoriatic Arthritis
Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
Rheumatoid arthritis (RA) is an inflammatory form of arthritis that causes joint pain and damage. RA attacks the lining of the joints (synovium), causing swelling that can result in aching and throbbing, and eventually deformity.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Periodontal Disease
- Trial name
- NCT01198509
- Testing
- doxycycline, vancomycin
- Where
- 2 sites in United States
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Breast Cancer
Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00622466
- Testing
- paclitaxel, sorafenib tosylate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Texas Southwestern Medical Center
Acne Vulgaris
Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel
To compare the tolerability of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% to Retin-A Micro® (tretinoin gel) microsphere when used by subjects with acne vulgaris for 3 weeks in terms of local tolerability parameters…
- Trial name
- NCT01522456
- Testing
- Epiduo Gel, Retin-A Micro Microsphere 0.1%
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Galderma R&D
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
This phase II trial studies the side effects and how well trebananib works in treating patients with persistent or recurrent endometrial cancer.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
- Trial name
- NCT01210222
- Testing
- Trebananib
- Where
- 33 sites in United States
- Volunteers
- 35 people
- Sponsor
- Gynecologic Oncology Group
Rheumatoid Arthritis
A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
An open ended study in which patients who completed the double-blind study CDP870-027 [NCT00152386] are given Certolizumab Pegol (CZP) and assessed for signs and symptoms of Rheumatoid Arthritis (RA).
- Trial name
- NCT00175877
- Testing
- Certolizumab Pegol
- Where
- 121 sites in United States, Argentina and 20 more
- Volunteers
- 857 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis, Cardiovascular Disease
Lipids, Inflammation, and CV Risk in RA
The objective of this study was to examine the relationship between inflammation, lipids, and cardiovascular risk in rheumatoid arthritis.
- Trial name
- LiiRA (NCT02714881)
- Testing
- Certolizumab
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Brigham and Women's Hospital
Metastatic Breast Cancer
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
The purpose of this study is to determine the recommended phase 2 dose and overall safety and tolerability of TRC105 when given in combination with capecitabine for the treatment of patients with progressive or recurrent…
- Trial name
- TRC105 (NCT01326481)
- Testing
- TRC105, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Pre-diabetes, Breast Cancer
Time Restricted Eating on Cancer Risk
Participants will be randomly assigned to either the time restricted feeding group with a daily eating period of 8 hours or the control group with a daily eating period of greater than or equal to 12 hours.
- Conditions
- Pre-diabetes, Breast Cancer, Time Restricted Feeding
- Trial name
- TREC (NCT05038137)
- Testing
- Time restricted feeding, Control
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Medical University of South Carolina
Venous Leg Ulcer
VLU Dressing Study
The goal of the study is to investigate the effectiveness of Cutimed Sorbact (Study Device) in modifying bacterial load in venous leg ulcers (VLU).
- Trial name
- NCT03621592
- Testing
- Cutimed® Sorbact®, Acticoat®
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Miami
Psoriasis
Safety and Tolerability Study of MSC Exosome Ointment
This phase 1 study aims to evaluate the safety and tolerability of the application of the MSC exosome ointment with repeated topical application on adult healthy subjects (TID from Day 1 to 20).
- Trial name
- NCT05523011
- Testing
- Exosome ointment
- Where
- Singapore
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Paracrine Therapeutics Dermatology Pte. Ltd.
Breast Cancer
A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients
This is the phase 2 portion of a phase 1/2 trial, testing the use of pemetrexed and cyclophosphamide in combination for the treatment of advanced breast cancer.
- Trial name
- NCT00190671
- Testing
- pemetrexed, cyclophosphamide
- Where
- 13 sites in Austria, Czechia and 4 more
- Volunteers
- 103 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis
Thus study will test an experimental drug called Z-102 (combination of prednisolone and dipyridamole) to treat patients with moderate to severe rheumatoid arthritis.
- Trial name
- Synergy (NCT01369745)
- Testing
- Prednisolone, dipyridamole, Prednisone
- Where
- United States
- Volunteers
- 294 people
- Sponsor
- Zalicus
Metastatic Breast Cancer
Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC
This research study is studying radiation therapy in combination with an immunotherapy as a possible treatment for metastatic hormone receptor (HR) positive, HER2-negative breast cancer.
- Trial name
- NCT03051672
- Testing
- Pembrolizumab, Palliative radiotherapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Breast Cancer
A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)
This is a Phase III, multicenter, randomized, placebo-controlled trial designed to evaluate the efficacy and safety of bevacizumab in combination with chemotherapy compared with chemotherapy alone in subjects with previously…
- Trial name
- NCT00262067
- Testing
- Bevacizumab, Chemotherapy
- Where
- 92 sites in United States, Australia and 20 more
- Volunteers
- 1,237 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.